The XMeNa patent protects an improved method for producing Oasmia’s nanotechnology platform XR-17, a drug-delivery system currently used with paclitaxel and other cancer drugs.
The patent is important for Oasmia as it expands the territories for exclusivity of the key technology XR‑17 used in our lead product Apealea (paclitaxel micellar), which is being launched in key markets globally.
“The XMeNa patent is already approved in several major pharmaceutical markets, including the US. With the XMeNa patent now approved in Australia, Oasmia has secured valuable IP protection for the major Oceania market with a significant pharmaceutical market,” says Francois Martelet, Chief Executive Officer of Oasmia.
“Water Soluble” patent granted in Brazil
The newly approved “Water soluble” patent is related to a novel nanoparticular formulation of a water soluble pharmaceutically active substances, such as doxorubicin, in combination with Oasmia’s patented technology XR-17. Doxorubicin is used to treat a variety of different forms of cancer such as acute lymphoblastic leukemia, acute myeloblastic leukemia, chronic leukemia, Hodgkin’s disease and non-Hodgkin’s lymphoma, amongst others.
The patent is also related to the product candidate Doxophos Vet which Oasmia developed for the treatment of lymphoma, the most common cancer in dogs.
Brazil is among the Top 10 Pharmaceutical Markets Worldwide and Oasmia is now positioned to secure market exclusivity in Brazil under its national patent law.
“Tax-dox-mix” patent receives notice of allowance in Brazil
The tax-dox-mix patent is related to the Oasmia project OAS-19 and focuses on the treatment of various cancers in humans. The patent covers a combination of a wide range of water soluble and water insoluble chemotherapeutic drugs in a single XR-17 containing solution. With an innovative dual chemotherapeutic agent encapsulation and release mechanism, this approach is intended to allow the administration of one single infusion containing two active pharmaceutical ingredients.
Photo of Francois Martelet: Oasmia